In addition to this Phase III study, two other GLP-1 receptor agonists (that are each already approved for use in treating diabetes type II) are also in clinical trials in specific PD patient subgroups, and as a direct consequence of the iLCT program. This evidence concerns the gene GLP1R and Parkinson disease.